The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.
C4 Therapeutics, a US-based small molecule drug developer spun out of the Harvard-affiliated Dana-Farber Cancer Institute, completed a $170m financing round yesterday.
Investment firm Cobro Ventures and hedge fund Perceptive Advisors co-led the $150m series B equity portion of the round, which also featured undisclosed existing investors, while Perceptive Advisors also supplied $20m in debt financing.
Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E Bioventures Capital, HBM Healthcare Investments, Lightchain Capital, Logos Capital, Mizuho Securities Principal Investment and Nextech also participated in the series B round.
The equity portion was rounded off by RA Capital Management, RTW Investments, Sphera Funds Management, Taiwania Capital Management, Yonjin Venture, and funds and accounts managed by T. Rowe Price and Janus Henderson Investors.
C4 is working on small molecule therapeutics designed to degrade and eventually destroy proteins that cause disease. The funding will support the advancement…
